Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 33 (10), 4521-9

Free Circulating DNA as a Biomarker of Prostate Cancer: Comparison of Quantitation Methods

Affiliations
  • PMID: 24123025
Comparative Study

Free Circulating DNA as a Biomarker of Prostate Cancer: Comparison of Quantitation Methods

Kavitha Ramachandran et al. Anticancer Res.

Abstract

Aim: To identify a simpler method of free circulating DNA (fcDNA) quantitation that may improve the specificity of the prostate cancer prostate-specific antigen (PSA) screening test.

Materials and methods: The patient group consisted of 241 men with elevated PSA/abnormal digital rectal exam (DRE), undergoing prostate biopsy. Serum fcDNA levels were measured by UV absorbance and PicoGreen. Results were compared to previously published quantitative polymerase chain reaction (qPCR) data.

Results: We found that levels of fcDNA measured by PicoGreen correlated well with those measured by qPCR (r=0.8552). In the patient group with PSA >4 to 10 ng/ml, those with fcDNA (PicoGreen) >53.1 ng/ml were at increased risk for prostate cancer compared to those with fcDNA ≤ 53.1 ng/ml. Moreover, we found that measuring fcDNA levels by PicoGreen does not compromise the negative predictive value, accuracy or specificity of the qPCR fcDNA test.

Conclusion: If validated in larger studies, PicoGreen quantitation of fcDNA could serve as a simple method to aid in prostate cancer diagnosis.

Keywords: PicoGreen; Prostate cancer; biomarker; cell-free DNA; quantitative PCR; screening.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

Publication types

Feedback